A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression

C. P. Larsen, S. J. Knechtle, A. Adams, T. Pearson, A. D. Kirk

Research output: Contribution to journalShort surveypeer-review

124 Scopus citations

Abstract

Activated T cells orchestrate the immune response that results in graft rejection; therefore, a common goal among current immunosuppressive therapies is to block T-cell activation, proliferation and function. Current immunosuppressive regimens that inhibit T cells and immune cells have greatly reduced the incidence of acute rejection following solid-organ transplant. However, the expected improvements in long-term outcomes have not been realized. This may be related to the non-immune side effects of current maintenance immunosuppressants, which target ubiquitously expressed molecules. The focus in transplantation research is shifting in search of maintenance immunosuppressive regimens that might offer improved long-term outcomes by providing efficacy in prevention of acute rejection combined with reduced toxicities. An emerging therapeutic strategy involves an immunoselective maintenance immunosuppressant that inhibits full T-cell activation by blocking the interaction between costimulatory receptor-ligand pairs. This review describes costimulatory pathways and the development of molecules, which inhibit them in the context of transplantation research. Recent clinical data using the selective costimulation blocker, belatacept (LEA29Y), as a part of a CNI-free maintenance immunosuppressive regimen in renal transplantation is highlighted.

Original languageEnglish (US)
Pages (from-to)876-883
Number of pages8
JournalAmerican Journal of Transplantation
Volume6
Issue number5 I
DOIs
StatePublished - May 2006
Externally publishedYes

Keywords

  • Co-stimulation
  • Kidney transplantation
  • T cell activation

Fingerprint

Dive into the research topics of 'A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression'. Together they form a unique fingerprint.

Cite this